CELG News and Press, Celgene Corporation From 11/19/19

NEW YORK , Nov. 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO) will replace Celgene Corp. (NASD: CELG) in the S&P 100, and ServiceNow Inc. (NYSE: NOW) will replace Celgene in the S&P 500 prior to the open of trading on Thursday, November 21.  Bristol-Myers ...

Four times a year, I spend several hours combing through Form 13F filings from the hedge funds that specialize in M&A. I document and analyze which merger stocks the funds have bought and which ones they haven't. I then compile the top 10 stocks held in these funds and share it with everyo...

S&P is making a small shuffle to two key stock indexes to account for Bristol-Myers Squibb's deal to acquire Celgene (NASDAQ: CELG ). More news on: Celgene Corporation, Thermo Fisher Scientific Inc., ServiceNow, Inc., Stocks on the move Read more ...

NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ ) today announced that Exelon Corporation (Nasdaq: EXC), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) and the NASDAQ-100 Ex-Tech Sector Index (Nasdaq:...

This article is part of a series that provides an ongoing analysis of the changes made to George Soros’s 13F stock portfolio on a quarterly basis. It is based on George Soros’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Soros Fund Management Holdings ar...

Merger activity increased with seven new deals announced and two deals closing. Deal Statistics New Deals The acquisition of Carbonite (CARB) by Open Text Corporation (OTEX) for $1.42 billion or $23.00 per share in cash. We added CARB as a potential deal to the Deals in the Work...

The U.S. Federal Trade Commission (FTC) says Celgene's ( CELG ) divestment of psoriasis med Otezla (apremilast) will settle its charges that its planned merger with Bristol-Myers Squibb (NYSE: BMY ) would violate federal antitrust law. More news on: Celgene Corporation, Amgen Inc., Brist...

CRISPR/Cas9 gene editor Editas Medicine ( EDIT +4% ) is up on average volume, adding to yesterday's  9%  jump after it announced an amended collaboration agreement with Celgene ( CELG ) aimed at researching, developing and commercializing autologous and allogeneic alpha-beta T ...

Editas Medicine  (NASDAQ: EDIT)  released third-quarter 2019 results on Tuesday morning. At first glance, its revenue and earnings numbers appeared to detail a terrible quarter, notably with a steep decline in revenue and widening generally accepted accounting principles ( GAAP ) los...

Investment Thesis Imetelstat of Geron Corporation ( GERN ), with its superior therapeutic efficacy, as proven in a phase 2 trial, looks promising for a largely under-served MDS (myelodysplastic syndromes) market. With only a single drug in the pipeline focusing on two rare forms of blood c...